| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10158575 | Pulmonary Pharmacology & Therapeutics | 2018 | 6 Pages |
Abstract
The DBAI generated highly respirable aerosols containing albuterol sulfate that were similar to the MDI and SMI in respirable fraction but lower in dose. Subsequent pharmacodynamic studies delivering albuterol sulfate alone and in combination with ipratropium bromide confirmed similar responses for the DBAI compared with the other inhalers, which could possibly be related to a response ceiling. The DBAI breath-activated capability combined with the ability to monitor actual delivery of medication may improve effectiveness by overcoming patient miscoordination.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Steven Kesten, Elliot Israel, Guangxi Li, Jolyon Mitchell, Robert Wise, Tom Stern,